|
|
Etienne Perold has a background in venture development, leadership consulting, and strategic relationships. He cofounded several technology-based firms in health care and communications, and has prior experience in board and executive committee roles in public, private, and not-for-profit firms.
Donald C. Monkhouse is an internationally respected practitioner in the field of pharmaceutical dosage form design. Over the past 33 years, Don shepherded and developed a multitude of prescription and OTC modified release products that were successfully manufactured and taken to market. He directed diverse aspects of Pharmaceutical R&D at Pfizer, Squibb, Sterling and SmithKline Beecham.
Michael King has a diverse background in corporate finance, investment banking, management consulting (McKinsey & Company), Board roles, and as a pharmaceutical company executive. Prior to joining Aprecia, Michael was a member of the US Executive Committee and Head of US Strategic Planning for Sandoz, the generic pharmaceutical subsidiary of Novartis AG.
Henry L. Surprenant has more than 25 years experience in developing pharmaceutical products based on his expertise in analytical and pharmaceutical chemistry. He was previously at Schering-Plough, and a Group Director at SmithKline Beecham. Hank was a key driver of the successful FDA filing and subsequent clearance of the first 3DP-derived product line.
Jae D. Yoo has more than 12 years experience in developing and evolving 3DP as a commercially viable technology. Jae worked closely with the original inventors of the 3DP process and pioneered the use of techniques to achieve spatial compositional control.